New Nordic Healthbrands AB Logo

New Nordic Healthbrands AB

Develops and markets herbal supplements & beauty products for natural wellness consumers globally.

NNH | ST

Overview

Corporate Details

ISIN(s):
SE0001838038
LEI:
213800JGTLNSKRD49G44
Country:
Sweden
Address:
SÖDRA FÖRSTADSGATAN 3, 211 43 MALMÖ
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

New Nordic Healthbrands AB is a company specializing in the development, marketing, and sale of herbal-based dietary supplements, natural remedies, and beauty products. Since its establishment in 1990, the company has focused on leveraging its expertise in medicinal plants to create innovative products that address specific health and beauty needs. New Nordic emphasizes scientific validation and quality control, analyzing all ingredients in controlled laboratories to ensure the safety and effectiveness of its offerings. The company markets its distinct brands globally to consumers seeking natural wellness solutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all New Nordic Healthbrands AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for New Nordic Healthbrands AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for New Nordic Healthbrands AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-05-16 Karl Kristian Bergman Jensen Other Sell 5,000 115,000.00 SEK
2025-03-12 Karl Kristian Bergman Jensen Other Sell 5,000 74,900.00 SEK
2025-03-11 Karl Kristian Bergman Jensen Other Sell 5,000 79,500.00 SEK
2025-03-05 Karl Kristian Bergman Jensen Other Sell 5,000 81,250.00 SEK
2025-01-22 Karl Kristian Bergman Jensen Other Sell 5,000 73,300.00 SEK
2025-01-21 Karl Kristian Bergman Jensen Other Sell 5,000 73,500.00 SEK
2025-01-20 Karl Kristian Bergman Jensen Other Sell 5,000 73,500.00 SEK
2024-12-27 Karl Kristian Bergman Jensen Other Sell 5,000 74,050.00 SEK
2024-12-18 Karl Kristian Bergman Jensen Other Sell 5,000 73,300.00 SEK
2024-09-06 Karl Kristian Bergman Jensen Other Sell 4,000 61,960.00 SEK

Peer Companies

NOVAVAX INC Logo
Develops and commercializes nanoparticle vaccines for serious infectious diseases.
United States of America
NVAX
Develops first-in-class drugs and supplements for metabolic and fibrotic diseases.
South Korea
229500
Novo Nordisk Logo
Develops medicines and devices for chronic diseases like diabetes, obesity, and rare disorders.
Denmark
NOVO
NRX Pharmaceuticals, Inc. Logo
Develops novel oral drugs for CNS disorders, targeting suicidal depression and PTSD.
United States of America
NRXP
NuCana plc Logo
Develops safer anti-cancer medicines with ProTide technology to overcome cell resistance.
United States of America
NCNA
NUTEX Investments Plc Logo
Develops & distributes health, cosmetic & pharma products from natural ingredients globally.
Hungary
NUTEX
NutriBand Inc. Logo
Develops abuse-deterrent transdermal patches to make potent drug delivery safer.
United States of America
NTRB
Nuvalent, Inc. Logo
Designs targeted small molecule drugs for kinase-driven cancers to overcome treatment resistance.
United States of America
NUVL
Nuvation Bio Inc. Logo
A clinical-stage biopharma developing novel drugs for difficult-to-treat cancers.
United States of America
NUVB
Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT

Talk to a Data Expert

Have a question? We'll get back to you promptly.